News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc. Presents Phase 3 Pooled Analysis Of Once-Daily Aptiom® (Eslicarbazepine Acetate) As Adjunctive Treatment For Partial-Onset Seizures


12/9/2013 10:01:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a pooled analysis of three Phase 3, randomized, placebo-controlled trials (Studies 301, 302 and 304) evaluating the safety and efficacy of once-daily Aptiom® (eslicarbazepine acetate) as adjunctive treatment of partial-onset seizures. Key findings from the pooled Phase 3 studies showed that APTIOM demonstrated statistically significant improvements in standardized seizure frequency for 800 mg and 1,200 mg once-daily dosages versus placebo and higher responder rates (50% and 75% reductions) with APTIOM treatment versus placebo at the same dosages. These results were presented at the 67th Annual Meeting of the American Epilepsy Society (AES) taking place in Washington, D.C., December 6-10, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES